WO2024118564A1 - Inhibiteurs de checkpoint kinase 1 (chk1) et leurs utilisations - Google Patents

Inhibiteurs de checkpoint kinase 1 (chk1) et leurs utilisations Download PDF

Info

Publication number
WO2024118564A1
WO2024118564A1 PCT/US2023/081279 US2023081279W WO2024118564A1 WO 2024118564 A1 WO2024118564 A1 WO 2024118564A1 US 2023081279 W US2023081279 W US 2023081279W WO 2024118564 A1 WO2024118564 A1 WO 2024118564A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
cycloalkyl
pharmaceutically acceptable
tautomer
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/081279
Other languages
English (en)
Inventor
Anthony B. Pinkerton
Stephen Todd MEYER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boundless Bio Inc
Original Assignee
Boundless Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boundless Bio Inc filed Critical Boundless Bio Inc
Publication of WO2024118564A1 publication Critical patent/WO2024118564A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • Chk1 is a central component of genome surveillance pathways and is a key regulator of the cell cycle and cell survival. Chk1 is required for the initiation of DNA damage checkpoints and has recently been shown to play a role in the normal (unperturbed) cell cycle. Chk1 impacts various stages of the cell cycle including the S phase, G2/M transition, and M phase. In addition to mediating cell cycle checkpoints, Chk1 also contributes to DNA repair processes, gene transcription, embryo development, cellular responses to HIV infection and somatic cell viability. [0004] Chk1 is essential for the maintenance of genomic integrity.
  • Chk1 monitors DNA replication in unperturbed cell cycles and responds to genotoxic stress if present. Chk1 recognizes DNA strand instability during replication and can stall DNA replication to allow time for DNA repair mechanisms to restore the genome. Recently, Chk1 has been shown to mediate DNA repair mechanisms and does so by activating various repair factors. Furthermore, Chk1 has been associated with three particular aspects of the S-phase, which includes the regulation of late origin firing, controlling the elongation process and maintenance of DNA replication fork stability. [0005] In response to DNA damage, Chk1 is an important signal transducer for G2/M checkpoint activation. Activation of Chk1 holds the cell in the G2 phase until ready to enter the mitotic phase.
  • Chk1 must inactivate for the cell to transition from the G2 phase into mitosis, Chk1 expression levels are mediated by regulatory proteins. [0006] Chk1 has a regulatory role in the spindle checkpoint; however, the relationship is less clear as compared to checkpoints in other cell cycle stages. During this phase, the Chk1 activating element of single strand DNA (ssDNA) cannot be generated suggesting an alternate form of activation. Studies on Chk1 deficient chicken lymphoma cells have shown increased levels of genomic instability and failure to arrest Attorney Docket No.57547-723.601 during the spindle checkpoint phase in mitosis.
  • Chk1 depletion can lead to defects in the spindle checkpoint resulting in mitotic abnormalities.
  • DNA damage induces the activation of Chk1, which facilitates the initiation of the DNA damage response (DDR) and cell cycle checkpoints.
  • the DNA damage response is a network of signaling pathways that leads to activation of checkpoints, DNA repair and apoptosis to inhibit damaged cells from progressing through the cell cycle.
  • Chk1 is regulated by ATR through phosphorylation, forming the ATR-Chk1 pathway.
  • This pathway recognizes ssDNA, which can be a result of UV-induced damage, replication stress and inter-strand cross linking. Often ssDNA can be a result of abnormal replication during S phase through the uncoupling of replication enzymes helicase and DNA polymerase. These ssDNA structures attract ATR and eventually activate the checkpoint pathway. [0009] However, activation of Chk1 is not solely dependent on ATR; intermediate proteins involved in DNA replication are often necessary. Regulatory proteins such as replication protein A, Claspin, Tim/Tipin, Rad 17, TopBP1 may be involved to facilitate Chk1 activation. Additional protein interactions are involved to induce maximal phosphorylation of Chk1.
  • Chk1 activation can also be ATR-independent through interactions with other protein kinases such as PKB/AKT, MAPKAPK and p90/RSK.
  • Chk1 interacts with many downstream effectors to induce cell cycle arrest.
  • Chk1 primarily phosphorylates Cdc25 which results in its proteasomal degradation. The degradation has an inhibitory effect on the formation of cyclin-dependent kinase complexes, which are key drivers of the cell cycle.
  • Cdc25 Through targeting Cdc25, cell cycle arrest can occur at multiple time points including the G1/S transition, S phase and G2/M transition.
  • Chk1 can target Cdc25 indirectly through phosphorylating Nek11.
  • Chk1 has shown to mediate DNA repair mechanisms and does so by activating repair factors such as proliferating cell nuclear antigen (PCNA), FANCE, Rad51 and TLK. Chk1 facilitates replication fork stabilization during DNA replication and repair however more research is necessary to define the underlying interactions.
  • PCNA proliferating cell nuclear antigen
  • FANCE FANCE
  • Rad51 Rad51
  • TLK TLK
  • Chk1 inhibitors that are potent inhibitors of the cell cycle checkpoints that can act effectively as potentiators of DNA damaging agents to address the need for safe and effective treatments of cancer.
  • the compound is of Formula (Ia): Formula (Ia).
  • the compound is of Formula (Ib): Formula (Ib).
  • the compound is of Formula (Ic): Formula (Ic).
  • the compound is of Formula (Id): Attorney Docket No.57547-723.601 Formula (Id).
  • a pharmaceutical composition comprising a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and a pharmaceutically acceptable excipient.
  • a method of treating cancer in a subject comprising administering to the subject a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, or a pharmaceutical composition disclosed herein.
  • the cancer is brain tumor. In some embodiments, the cancer has metastasized in the brain.
  • Also disclosed herein is a method for treating a tumor or tumor cells in a subject, the method comprising administering a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, in an amount sufficient to induce replication stress in the tumor or tumor cells; and administering a cancer-targeted therapeutic agent; wherein the tumor or tumor cells have an ecDNA signature; and wherein growth or size of the tumor or growth or number of tumor cells is reduced.
  • Also disclosed herein is a method for treating a tumor or tumor cells in a subject, the method comprising administering a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof; and administering a cancer-targeted therapeutic agent; wherein the tumor or tumor cells have an ecDNA signature; and wherein growth or size of the tumor or growth or number of tumor cells is reduced.
  • the compound or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof is administered in an amount sufficient to induce replication stress in the tumor or tumor cells.
  • Also disclosed herein is a method of treating an ecDNA-associated tumor or tumor cells comprising administering a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, to a subject identified as having a tumor or tumor cells having ecDNA, wherein growth or size of the tumor or growth or number of the tumor cells is decreased as a result of treatment.
  • the method further comprises administering a cancer-targeted therapeutic agent.
  • the compound is CNS penetrant.
  • Also disclosed herein is a method of inhibiting Chk1 in a subject, comprising administering to the subject a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, or a pharmaceutical composition disclosed herein.
  • Also disclosed herein is a method of treating tumor or tumor cells having a focal amplification of a target gene comprising administering a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, to a subject identified as having a tumor or tumor cells having the focal amplification, wherein growth or size of the tumor or growth or number of the tumor cells is decreased as a result of treatment.
  • the method further comprises administering a cancer-targeted therapeutic agent directed against the target gene.
  • the focal amplification is present on ecDNA.
  • Also disclosed herein is a method of treating tumor or tumor cells that have developed resistance to a targeted agent comprising administering a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, to a subject identified as having a tumor or tumor cells that have developed resistance to the targeted agent, wherein growth or size of the tumor or growth or number of the tumor cells is decreased as a result of treatment.
  • the method further comprises administering the targeted agent.
  • the targeted agent is directed against a target gene present within a focal amplification and/or on ecDNA.
  • Alkyl refers to a straight-chain or branched-chain saturated hydrocarbon monoradical having from one to about ten carbon atoms, more preferably one to six carbon atoms. Examples include, but are not limited to methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3- methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1- pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1- butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-penty
  • a numerical range such as “C1-C6 alkyl” or “C1-6alkyl” means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated.
  • the alkyl is a C 1-10 alkyl.
  • the alkyl is a C 1-6 alkyl.
  • the alkyl is a C 1-5 alkyl.
  • the alkyl is a C 1-4 alkyl.
  • the alkyl is a C 1-3 alkyl.
  • an alkyl group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
  • the alkyl is optionally substituted with oxo, halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH 2 , or -NO 2 .
  • alkyl is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkyl is optionally substituted with halogen.
  • alkenyl refers to a straight-chain, or branched-chain hydrocarbon monoradical having one or more carbon-carbon double-bonds and having from two to about ten carbon atoms, more preferably two to about six carbon atoms. The group may be in either the cis or trans conformation about the double bond(s), and should be understood to include both isomers.
  • a numerical range such as “C 2 -C 6 alkenyl” or “C 2-6 alkenyl”, means that the alkenyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkenyl” where no numerical range is designated.
  • an alkenyl group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
  • the Attorney Docket No.57547-723.601 alkenyl is optionally substituted with oxo, halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH 2 , or -NO 2 .
  • alkenyl is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkenyl is optionally substituted with halogen.
  • Alkynyl refers to a straight-chain or branched-chain hydrocarbon monoradical having one or more carbon-carbon triple-bonds and having from two to about ten carbon atoms, more preferably from two to about six carbon atoms. Examples include, but are not limited to ethynyl, 2-propynyl, 2-butynyl, 1,3- butadiynyl and the like.
  • an alkynyl group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
  • the alkynyl is optionally substituted with oxo, halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH2, or -NO2.
  • the alkynyl is optionally substituted with halogen, -CN, - OH, or -OMe.
  • alkynyl is optionally substituted with halogen.
  • Alkylene refers to a straight or branched divalent hydrocarbon chain. Unless stated otherwise specifically in the specification, an alkylene group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
  • the alkylene is optionally substituted with oxo, halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkylene is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkylene is optionally substituted with halogen. [0042] “Alkoxy” refers to a radical of the formula -OR a where R a is an alkyl radical as defined.
  • an alkoxy group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
  • the alkoxy is optionally substituted with halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH 2 , or -NO 2 .
  • the alkoxy is optionally substituted with halogen, -CN, -OH, or -OMe.
  • the alkoxy is optionally substituted with halogen.
  • Aryl refers to a radical derived from a hydrocarbon ring system comprising 6 to 30 carbon atoms and at least one aromatic ring.
  • the aryl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused (when fused with a cycloalkyl or heterocycloalkyl ring, the aryl is bonded through an aromatic ring atom) or bridged ring systems.
  • the aryl is a 6- to 10- membered aryl.
  • the aryl is a 6-membered aryl (phenyl).
  • Aryl radicals include, but are not limited to, aryl radicals derived from the hydrocarbon ring systems of anthrylene, naphthylene, phenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene.
  • an aryl may be optionally substituted, for example, with halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
  • the aryl is optionally substituted with halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF 3 , -OH, -OMe, -NH 2 , or -NO 2 .
  • the aryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF 3 , -OH, or -OMe. In some embodiments, the aryl is optionally substituted with halogen.
  • Cycloalkyl refers to a partially or fully saturated, monocyclic, or polycyclic carbocyclic ring, which may include fused (when fused with an aryl or a heteroaryl ring, the cycloalkyl is bonded through a non-aromatic ring atom) or bridged ring systems. In some embodiments, the cycloalkyl is fully saturated.
  • Representative cycloalkyls include, but are not limited to, cycloalkyls having from three to fifteen carbon atoms (C3-C15 cycloalkyl or C3-C15 cycloalkenyl), from three to ten carbon atoms (C3-C10 cycloalkyl or C3- C10 cycloalkenyl), from three to eight carbon atoms (C3-C8 cycloalkyl or C3-C8 cycloalkenyl), from three to six carbon atoms (C3-C6 cycloalkyl or C3-C6 cycloalkenyl), from three to five carbon atoms (C3-C5 cycloalkyl or C3-C5 cycloalkenyl), or three to four carbon atoms (C3-C4 cycloalkyl or C3-C4 cycloalkenyl).
  • the cycloalkyl is a 3- to 10-membered cycloalkyl or a 3- to 10-membered cycloalkenyl. In some embodiments, the cycloalkyl is a 3- to 6-membered cycloalkyl or a 3- to 6-membered cycloalkenyl. In some embodiments, the cycloalkyl is a 5- to 6-membered cycloalkyl or a 5- to 6-membered cycloalkenyl.
  • Monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • Polycyclic cycloalkyls include, for example, adamantyl, norbornyl, decalinyl, bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, cis-decalin, trans-decalin, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, and bicyclo[3.3.2]decane, and 7,7- dimethyl-bicyclo[2.2.1]heptanyl.
  • Partially saturated cycloalkyls include, for example cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl.
  • a cycloalkyl is optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
  • a cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2.
  • a cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe.
  • the cycloalkyl is optionally substituted with halogen.
  • Halo or “halogen” refers to bromo, chloro, fluoro or iodo.
  • halogen is fluoro or chloro. In some embodiments, halogen is fluoro.
  • Haloalkyl refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2- trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like.
  • Hydroxyalkyl refers to an alkyl radical, as defined above, that is substituted by one or more hydroxyls. In some embodiments, the alkyl is substituted with one hydroxyl. In some embodiments, the alkyl is substituted with one, two, or three hydroxyls. Hydroxyalkyl include, for example, hydroxymethyl, Attorney Docket No.57547-723.601 hydroxyethyl, hydroxypropyl, hydroxybutyl, or hydroxypentyl. In some embodiments, the hydroxyalkyl is hydroxymethyl. [0048] “Aminoalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more amines.
  • the alkyl is substituted with one amine. In some embodiments, the alkyl is substituted with one, two, or three amines.
  • Aminoalkyl include, for example, aminomethyl, aminoethyl, aminopropyl, aminobutyl, or aminopentyl. In some embodiments, the aminoalkyl is aminomethyl.
  • “Deuteroalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more deuteriums. In some embodiments, the alkyl is substituted with one deuterium. In some embodiments, the alkyl is substituted with one, two, or three deuteriums.
  • the alkyl is substituted with one, two, three, four, five, or six deuteriums.
  • Deuteroalkyl include, for example, CD3, CH2D, CHD2, CH2CD3, CD2CD3, CHDCD3, CH2CH2D, or CH2CHD2.
  • the deuteroalkyl is CD3.
  • “Heteroalkyl” refers to an alkyl group in which one or more skeletal atoms of the alkyl are selected from an atom other than carbon, e.g., oxygen, nitrogen (e.g., -NH-, -N(alkyl)-), sulfur, phosphorus, or combinations thereof.
  • a heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalkyl.
  • a heteroalkyl is a C1-C6 heteroalkyl wherein the heteroalkyl is comprised of 1 to 6 carbon atoms and one or more atoms other than carbon, e.g., oxygen, nitrogen (e.g. -NH-, -N(alkyl)-), sulfur, phosphorus, or combinations thereof wherein the heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalkyl.
  • heteroalkyl examples include, for example, -CH2OCH3, -CH2CH2OCH3, -CH2CH2OCH2CH2OCH3, -CH(CH3)OCH3, -CH2NHCH3, -CH2N(CH3)2, -CH2CH2NHCH3, or - CH2CH2N(CH3)2.
  • a heteroalkyl is optionally substituted for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
  • a heteroalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, a heteroalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF 3 , -OH, or - OMe. In some embodiments, the heteroalkyl is optionally substituted with halogen.
  • Heterocycloalkyl refers to a 3- to 24-membered partially or fully saturated ring radical comprising 2 to 23 carbon atoms and from one to 8 heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorous and sulfur. In some embodiments, the heterocycloalkyl is fully saturated. In some embodiments, the heterocycloalkyl comprises one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, the heterocycloalkyl comprises one to three heteroatoms selected from the group consisting of nitrogen and oxygen. In some embodiments, the heterocycloalkyl comprises one to three nitrogens. In some embodiments, the heterocycloalkyl comprises one or two nitrogens.
  • the heterocycloalkyl comprises one nitrogen. In some embodiments, the heterocycloalkyl comprises one nitrogen and one oxygen.
  • the heterocycloalkyl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused (when fused with an aryl or a heteroaryl ring, the heterocycloalkyl is bonded through a non-aromatic ring atom) or bridged ring systems; and the nitrogen, Attorney Docket No.57547-723.601 carbon, or sulfur atoms in the heterocycloalkyl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized.
  • heterocycloalkyls include, but are not limited to, heterocycloalkyls having from two to fifteen carbon atoms (C 2 -C 15 heterocycloalkyl or C 2 -C 15 heterocycloalkenyl), from two to ten carbon atoms (C 2 -C 10 heterocycloalkyl or C 2 -C 10 heterocycloalkenyl), from two to eight carbon atoms (C 2 -C 8 heterocycloalkyl or C 2 -C 8 heterocycloalkenyl), from two to seven carbon atoms (C 2 -C 7 heterocycloalkyl or C 2 -C 7 heterocycloalkenyl), from two to six carbon atoms (C 2 -C 6 heterocycloalkyl or C 2 - C 6 heterocycloalkenyl), from two to five carbon atoms (C 2 -C 5 heterocycloalkyl or C 2 -C 5 heterocycloalkenyl), or two to four carbon atoms (C 2 -C
  • heterocycloalkyl radicals include, but are not limited to, aziridinyl, azetidinyl, oxetanyl, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2- oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyr
  • heterocycloalkyl also includes all ring forms of the carbohydrates, including but not limited to the monosaccharides, the disaccharides, and the oligosaccharides. Unless otherwise noted, heterocycloalkyls have from 2 to 10 carbons in the ring. It is understood that when referring to the number of carbon atoms in a heterocycloalkyl, the number of carbon atoms in the heterocycloalkyl is not the same as the total number of atoms (including the heteroatoms) that make up the heterocycloalkyl (i.e. skeletal atoms of the heterocycloalkyl ring). In some embodiments, the heterocycloalkyl is a 3- to 8-membered heterocycloalkyl.
  • the heterocycloalkyl is a 3- to 7-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 3- to 6-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 4- to 6-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 5- to 6-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 3- to 8-membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 3- to 7-membered heterocycloalkenyl.
  • the heterocycloalkyl is a 3- to 6-membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 4- to 6-membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 5- to 6-membered heterocycloalkenyl.
  • a heterocycloalkyl may be optionally substituted as described below, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
  • the heterocycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2.
  • the heterocycloalkyl is optionally substituted with halogen, methyl, ethyl, -CN, -CF 3 , -OH, or -OMe. In some embodiments, the heterocycloalkyl is optionally substituted with halogen.
  • “Heteroaryl” refers to a 5- to 14-membered ring system radical comprising one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorous, and Attorney Docket No.57547-723.601 sulfur, and at least one aromatic ring. In some embodiments, the heteroaryl comprises one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur.
  • the heteroaryl comprises one to three heteroatoms selected from the group consisting of nitrogen and oxygen. In some embodiments, the heteroaryl comprises one to three nitrogens. In some embodiments, the heteroaryl comprises one or two nitrogens. In some embodiments, the heteroaryl comprises one nitrogen.
  • the heteroaryl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused (when fused with a cycloalkyl or heterocycloalkyl ring, the heteroaryl is bonded through an aromatic ring atom) or bridged ring systems; and the nitrogen, carbon, or sulfur atoms in the heteroaryl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized.
  • the heteroaryl is a 5- to 10-membered heteroaryl. In some embodiments, the heteroaryl is a 5- to 6-membered heteroaryl. In some embodiments, the heteroaryl is a 6-membered heteroaryl. In some embodiments, the heteroaryl is a 5- membered heteroaryl.
  • Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furany
  • a heteroaryl may be optionally substituted, for example, with halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
  • the heteroaryl is optionally substituted with halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2.
  • the heteroaryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the heteroaryl is optionally substituted with halogen.
  • the term “optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not.
  • “optionally substituted alkyl” means either “alkyl” or “substituted alkyl” as defined above.
  • an optionally substituted group may be un-substituted (e.g., - CH 2 CH 3 ), fully substituted (e.g., -CF 2 CF 3 ), mono-substituted (e.g., -CH 2 CH 2 F) or substituted at a level anywhere in-between fully substituted and mono-substituted (e.g., -CH 2 CHF 2 , -CH 2 CF 3 , -CF 2 CH 3 , - CFHCHF 2 , etc.).
  • any substituents described should generally be understood as having a maximum molecular weight of about 1,000 daltons, and more typically, up to about 500 daltons.
  • the term “one or more” when referring to an optional substituent means that the subject group is optionally substituted with one, two, three, four, or more substituents. In some embodiments, the subject group is optionally substituted with one, two, three, or four substituents. In some embodiments, the subject group is optionally substituted with one, two, or three substituents. In some embodiments, the subject group is optionally substituted with one or two substituents. In some embodiments, the subject group is optionally substituted with one substituent. In some embodiments, the subject group is optionally substituted with two substituents.
  • beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; diminishment of the extent of the condition, disorder or disease; stabilization (i.e., not worsening) of the state of the condition, disorder or disease; delay in onset or slowing of the progression of the condition, disorder or disease; amelioration of the condition, disorder or disease state; and remission (whether partial or total), whether detectable or undetectable, or enhancement or improvement of the condition, disorder or disease.
  • Treatment includes eliciting a clinically significant response without excessive levels of side effects. Treatment also includes prolonging survival as compared to expected survival if not receiving treatment.
  • the terms “treat,” “treated,” “treatment,” or “treating” as well as words stemming therefrom, as used herein, do not necessarily imply 100% or complete treatment. Rather, there are varying degrees of treatment of which one of ordinary skill in the art recognizes as having a potential benefit or therapeutic effect.
  • the disclosed methods can provide any amount of any level of treatment of the disorder in a mammal. For example, a disorder, including symptoms or conditions thereof, may be reduced by, for example, about 100%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, or about 10%.
  • an “effective amount” or “therapeutically effective amount,” as used herein, refer to a sufficient amount of a compound disclosed herein being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated, e.g., cancer or an inflammatory disease. In some embodiments, the result is a reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system.
  • an “effective amount” for therapeutic uses is the amount of the composition comprising a compound disclosed herein required to provide a clinically significant decrease in disease symptoms.
  • an appropriate “effective” amount in any individual case is determined using techniques, such as a dose escalation study.
  • ecDNA signature generally refers to one or more characteristics common to tumors or tumor cells that are ecDNA+.
  • the ecDNA signature is selected from Attorney Docket No.57547-723.601 the group consisting of a gene amplification; a p53 loss of function mutation; absence of microsatellite instability (MSI-H); a low level of PD-L1 expression; a low level of tumor inflammation signature (TIS); a low level of tumor mutational burden (TMB); an increased frequency of allele substitutions, insertions, or deletions (indels); and any combination thereof.
  • ecDNA signature includes a detection or identification of ecDNA using an imaging technology.
  • ecDNA signature does not include any imaging or direct detection of ecDNA.
  • the cancer is a brain tumor or is a cancer that has metastasized in the brain.
  • R W is halogen, -OH, -OR a , C1-C6alkyl, C1-C6haloalkyl, or cycloalkyl
  • R Y is C1-C6alkyl or cycloalkyl
  • the alkyl and cycloalkyl is optionally substituted with one or more R
  • each R a is independently C1-C6alkyl or C1-C6haloalkyl
  • each R is independently halogen, -CN, -OH, -OC 1 -C 3 alkyl, -OC 1 -C 3 haloalkyl, C 1 -C 3 alkyl, or C 1 -C 3 haloalkyl; or two R on the same atom form an oxo.
  • R W is halogen
  • R Y is C1-C6alkyl or cycloalkyl; wherein the alkyl and cycloalkyl is optionally substituted with one or more R; each R is independently halogen, -CN, -OH, -OC1-C3alkyl, -OC1-C3haloalkyl, C1-C3alkyl, or C1-C3haloalkyl; or two R on the same atom form an oxo.
  • the compound is of Formula (Ia): Attorney Docket No.57547-723.601 Formula (Ia).
  • the compound is of Formula (Ia’): Formula (Ia’).
  • the compound is of Formula (Ib): Formula (Ib).
  • the compound is of Formula (Ib’): Formula (Ib’).
  • the compound is of Formula (Ic): Attorney Docket No.57547-723.601 Formula (Ic).
  • the compound is of Formula (Ic’): Formula (Ic’). [0069] In some embodiments of a compound of Formula (I), the compound is of Formula (Id): Formula (Id). [0070] In some embodiments of a compound of Formula (I), the compound is of Formula (Id’): Formula (Id’). [0071] In some embodiments of a compound of Formula (I), (I’), (Ia)-(Id), or (Ia’)-(Id’), Ring A is aryl or heteroaryl.
  • Ring A is heteroaryl. In some embodiments of a compound of Formula (I), (I’), (Ia)-(Id), or (Ia’)-(Id’), Ring A is 6- membered heteroaryl. In some embodiments of a compound of Formula (I), (I’), (Ia)-(Id), or (Ia’)-(Id’), Ring A is pyrazinyl.
  • each R 1 is independently deuterium, halogen, -CN, -OH, -OR a , C1-C6alkyl, or C1-C6haloalkyl.
  • n is 0-2. In some embodiments of a compound of Formula (I), (I’), (Ia)-(Id), or (Ia’)-(Id’), n is 1 or 2.
  • n is 0 or 1. In some embodiments of a compound of Formula (I), (I’), (Ia)-(Id), or (Ia’)-(Id’), n is 0. In some embodiments of a compound of Formula (I), (I’), (Ia)-(Id), or (Ia’)-(Id’), n is 1. In some embodiments of a compound of Formula (I), (I’), (Ia)-(Id), or (Ia’)- (Id’), n is 2.
  • n is 3.
  • R 2 is hydrogen or C1-C6alkyl. In some embodiments of a compound of Formula (I), (I’), (Ia)-(Id), or (Ia’)-(Id’), R 2 is hydrogen.
  • R 3 is hydrogen, deuterium, halogen, C1-C6alkyl, or C1-C6haloalkyl. In some embodiments of a compound of Formula (I), (I’), (Ia)-(Id), or (Ia’)-(Id’), R 3 is hydrogen. [0076] In some embodiments of a compound of Formula (I), (I’), (Ia)-(Id), or (Ia’)-(Id’), R 4 is hydrogen or C 1 -C 6 alkyl.
  • R 4 is hydrogen.
  • R W is hydrogen, deuterium, halogen, -CN, -OH, - OR a , -NR c R d , C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, cycloalkyl, or heterocycloalkyl; wherein the alkyl, cycloalkyl and heterocycloalkyl is optionally substituted with one or more R.
  • R W is deuterium, halogen, -CN, -OH, -OR a , -NR c R d , C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, cycloalkyl, or heterocycloalkyl; wherein the alkyl, cycloalkyl and heterocycloalkyl is optionally substituted with one or more R.
  • R W is hydrogen, deuterium, halogen, -OH, -OR a , - NR c R d , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, or cycloalkyl.
  • R W is deuterium, halogen, -OH, -OR a , -NR c R d , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, or cycloalkyl.
  • R W is hydrogen, halogen, -OH, -OR a , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, or cycloalkyl.
  • R W is halogen, -OH, -OR a , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, or cycloalkyl. In some embodiments of a compound of Formula (I), (I’), (Ia)-(Id), or (Ia’)- (Id’), R W is halogen or C 1 -C 6 alkyl. In some embodiments of a compound of Formula (I), (I’), (Ia)-(Id), or (Ia’)-(Id’), R W is halogen.
  • R W is fluoro. In some embodiments of a compound of Formula (I), (I’), (Ia)-(Id), or (Ia’)-(Id’), R W is -OR a .
  • R X is hydrogen, deuterium, halogen, -CN, -OH, -OR a , -NR c R d , C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, cycloalkyl, or heterocycloalkyl; wherein the alkyl, cycloalkyl, and heterocycloalkyl is optionally substituted with one or more R.
  • R X is hydrogen, deuterium, halogen, -OH, -OR a , -NR c R d , C1-C6alkyl, C1-C6haloalkyl, or cycloalkyl.
  • R X is hydrogen, halogen, C1-C6alkyl, C1-C6haloalkyl, or cycloalkyl.
  • R X is hydrogen, halogen, or C1-C6alkyl. In some embodiments of a compound of Formula (I), (I’), (Ia)-(Id), or (Ia’)-(Id’), R X is hydrogen or halogen. In some embodiments of a compound of Formula (I), (I’), (Ia)-(Id), or (Ia’)-(Id’), R X is hydrogen or C1-C6alkyl.
  • R X is hydrogen.
  • R Y is deuterium, halogen, -CN, -OH, -OR a , -NR c R d , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 deuteroalkyl, C 1 -C 6 hydroxyalkyl, cycloalkyl, or heterocycloalkyl; wherein the alkyl, cycloalkyl, and heterocycloalkyl is optionally substituted with one or more R.
  • R Y is deuterium, halogen, -OH, -OR a , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, cycloalkyl, or heterocycloalkyl; wherein the alkyl, cycloalkyl, and heterocycloalkyl is optionally substituted with one or more R.
  • R Y is Attorney Docket No.57547-723.601 halogen, -OH, -OR a , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, or cycloalkyl; wherein the alkyl and cycloalkyl is optionally substituted with one or more R.
  • R Y is halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, or cycloalkyl; wherein the alkyl and cycloalkyl is optionally substituted with one or more R.
  • R Y is C 1 -C 6 alkyl or cycloalkyl; wherein the alkyl and cycloalkyl is optionally substituted with one or more R.
  • R Y is C 1 -C 6 alkyl optionally substituted with one or more R.
  • R Y is methyl.
  • R Y is cycloalkyl optionally substituted with one or more R.
  • R Y is cycloalkyl or heterocycloalkyl; wherein the cycloalkyl and heterocycloalkyl is optionally substituted with one or more R.
  • R Y is cyclopropyl optionally substituted with one or more R.
  • R Z is hydrogen, deuterium, halogen, -CN, -OH, -OR a , -NR c R d , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 deuteroalkyl, cycloalkyl, or heterocycloalkyl; wherein the alkyl, cycloalkyl, and heterocycloalkyl is optionally substituted with one or more R.
  • R Z is hydrogen, deuterium, halogen, -OH, -OR a , -NR c R d , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, or cycloalkyl.
  • R Z is hydrogen, deuterium, halogen, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl.
  • R Z is hydrogen, halogen, or C 1 -C 6 alkyl. In some embodiments of a compound of Formula (I), (I’), (Ia)-(Id), or (Ia’)-(Id’), R Z is hydrogen or halogen. In some embodiments of a compound of Formula (I), (I’), (Ia)-(Id), or (Ia’)-(Id’), R Z is hydrogen or C 1 -C 6 alkyl.
  • R Z is hydrogen.
  • each R a is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 deuteroalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, cycloalkyl, heterocycloalkyl, C 1 -C 6 alkylene(cycloalkyl), or C 1 -C 6 alkylene(heterocycloalkyl); wherein each alkyl, alkylene, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R.
  • each R a is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 deuteroalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, cycloalkyl, heterocycloalkyl; wherein each alkyl, alkylene, cycloalkyl, and heterocycloalkyl is independently optionally Attorney Docket No.57547-723.601 substituted with one or more R.
  • each R a is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 deuteroalkyl, C 1 -C 6 hydroxyalkyl, or C 1 -C 6 aminoalkyl.
  • each R a is independently C 1 -C 6 alkyl or C 1 -C 6 haloalkyl.
  • each R a is independently C 1 -C 6 alkyl.
  • each R b is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, cycloalkyl, heterocycloalkyl, C1-C6alkylene(cycloalkyl), or C1-C6alkylene(heterocycloalkyl); wherein each alkyl, alkylene, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R.
  • each R b is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, cycloalkyl, heterocycloalkyl; wherein each alkyl, alkylene, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R.
  • each R b is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, or C1-C6aminoalkyl.
  • each R b is independently hydrogen, C1-C6alkyl, or C1-C6haloalkyl.
  • each R b is independently hydrogen or C1-C6alkyl. In some embodiments of a compound of Formula (I), (I’), (Ia)-(Id), or (Ia’)-(Id’), each R b is independently hydrogen. In some embodiments of a compound of Formula (I), (I’), (Ia)-(Id), or (Ia’)-(Id’), each R b is independently C1-C6alkyl.
  • each R c and R d are independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, cycloalkyl, heterocycloalkyl, C1-C6alkylene(cycloalkyl), or C1-C6alkylene(heterocycloalkyl); wherein each alkyl, alkylene, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R.
  • each R c and R d are independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 deuteroalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, cycloalkyl, heterocycloalkyl; wherein each alkyl, alkylene, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R.
  • each R c and R d are independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 deuteroalkyl, C 1 -C 6 hydroxyalkyl, or C 1 -C 6 aminoalkyl.
  • each R c and R d are independently hydrogen, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl.
  • each R c and R d are independently hydrogen or C 1 -C 6 alkyl. In some embodiments of a compound of Formula (I), (I’), (Ia)-(Id), or (Ia’)-(Id’), each R c and R d are hydrogen. In some embodiments of a compound of Formula (I), (I’), (Ia)-(Id), or (Ia’)-(Id’), each R c and R d are independently C 1 -C 6 alkyl.
  • R c and R d are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R.
  • each R is independently halogen, -CN, -OH, -OC1- C3alkyl, -OC1-C3haloalkyl, -NH2, -NHC1-C3alkyl, -N(C1-C3alkyl)2, C1-C3alkyl, C1-C3haloalkyl, C1- C3deuteroalkyl, C1-C3hydroxyalkyl, C1-C3aminoalkyl, C1-C3heteroalkyl, or C3-C6cycloalkyl; or two R on the same atom form an oxo.
  • each R is independently halogen, -CN, -OH, -OC1-C3alkyl, -NH2, C1-C3alkyl, or C1-C3haloalkyl; or two R on the same atom form an oxo.
  • each R is independently halogen, -OH, C1-C3alkyl, or C1-C3haloalkyl; or two R on the same atom form an oxo.
  • each R is independently halogen, -OH, -NH2, C1-C3alkyl, or C1-C3haloalkyl; or two R on the same atom form an oxo.
  • each R is independently halogen, C1-C3alkyl, or C1-C3haloalkyl; or two R on the same atom form an oxo.
  • each R is independently halogen or C1-C3alkyl; or two R on the same atom form an oxo.
  • the compound is selected from a compound of Table 1: TABLE 1 Attorney Docket No.57547-723.601
  • the Chk1 inhibitor is CNS-penetrant.
  • a CNS- penetrant compound is a compound having a brain:plasma ratio greater than about 1. In some embodiments, the brain:plasma ratio is between about 1 and about 5.
  • the brain:plasma ratio is between about 1 and about 4. In some embodiments, the brain:plasma ratio is between about 1 and about 3. In some embodiments, the brain:plasma ratio is between about 1 and about 2. In some embodiments, the brain:plasma ratio is equal to about 1. In some embodiments, the brain:plasma ratio is equal to about 1.1. In some embodiments, the brain:plasma ratio is equal to about 1.2. In some embodiments, the brain:plasma ratio is equal to about 1.3. In some embodiments, the brain:plasma ratio is equal to about 1.4. In some embodiments, the brain:plasma ratio is equal to about 1.5. In some embodiments, the brain:plasma ratio is equal to about 1.6.
  • the brain:plasma ratio is equal to about 1.7. In some embodiments, the brain:plasma ratio is equal to about 1.8. In some embodiments, the brain:plasma ratio is equal to about 1.9. In some embodiments, the brain:plasma ratio is equal to about 2. In some embodiments, the brain:plasma ratio is equal to about 2.1. In some embodiments, the brain:plasma ratio is equal to about 2.2. In some embodiments, the brain:plasma ratio is equal to about 2.3. In some embodiments, the brain:plasma ratio is equal to about 2.4. In some embodiments, the brain:plasma ratio is equal to about 2.5. In some embodiments, the brain:plasma ratio is equal to about 2.6.
  • the brain:plasma ratio is equal to about 2.7. In some embodiments, the brain:plasma ratio is equal to about 2.8. In some embodiments, the brain:plasma ratio is equal to about 2.9. In some embodiments, the brain:plasma ratio is equal to about 3.
  • the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein possess one or more double bonds. The compounds presented herein include all cis, trans, syn, anti, Cyprus (E), and sixteen (Z) isomers as well as the corresponding mixtures thereof.
  • the compounds described herein possess one or more chiral centers and each center exists in the R configuration or S configuration.
  • the compounds described herein include all diastereomeric, enantiomeric, and epimeric forms as well as the corresponding mixtures thereof.
  • mixtures of enantiomers and/or diastereoisomers, resulting from a single preparative step, combination, or interconversion are useful for the applications described herein.
  • the compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers, and recovering the optically pure enantiomers.
  • dissociable complexes are preferred.
  • the diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and are separated by taking advantage of these dissimilarities.
  • the diastereomers are separated by chiral chromatography, or preferably, by Attorney Docket No.57547-723.601 separation/resolution techniques based upon differences in solubility.
  • the optically pure enantiomer is then recovered, along with the resolving agent.
  • Labeled compounds [0089]
  • the compounds described herein exist in their isotopically-labeled forms.
  • the methods disclosed herein include methods of treating diseases by administering such isotopically-labeled compounds.
  • the methods disclosed herein include methods of treating diseases by administering such isotopically-labeled compounds as pharmaceutical compositions.
  • the compounds disclosed herein include isotopically-labeled compounds, which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into compounds described herein, or a solvate, tautomer, or stereoisomer thereof, include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, and chloride, such as 2 H, 3 H, 13 C, 14 C, l5 N, 18 O, 17 O, 31 P, 32 P, 35 S, 18 F, and 36 Cl, respectively.
  • the isotopically labeled compound or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof is prepared by any suitable method.
  • the compounds described herein are labeled by other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.
  • Pharmaceutically acceptable salts [0091] In some embodiments, the compounds described herein exist as their pharmaceutically acceptable salts.
  • the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts as pharmaceutical compositions.
  • the compounds described herein possess acidic or basic groups and therefor react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt. In some embodiments, these salts are prepared in situ during the final isolation and purification of the compounds disclosed herein, or by separately reacting a purified compound in its free form with a suitable acid or base, and isolating the salt thus formed.
  • Examples of pharmaceutically acceptable salts include those salts prepared by reaction of the compounds described herein with a mineral, organic acid, or inorganic base, such salts including acetate, acrylate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, bisulfite, bromide, butyrate, butyn-1,4-dioate, camphorate, camphorsulfonate, caproate, caprylate, chlorobenzoate, chloride, citrate, cyclopentanepropionate, decanoate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hex
  • the compounds described herein can be prepared as pharmaceutically acceptable salts formed by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, including, but not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid metaphosphoric acid, and the like; and organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, p-toluenesulfonic acid, tartaric acid, trifluoroacetic acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, arylsulfonic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-
  • those compounds described herein that comprise a free acid group react with a suitable base, such as the hydroxide, carbonate, bicarbonate, or sulfate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, tertiary, or quaternary amine.
  • a suitable base such as the hydroxide, carbonate, bicarbonate, or sulfate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, tertiary, or quaternary amine.
  • Representative salts include the alkali or alkaline earth salts, like lithium, sodium, potassium, calcium, and magnesium, and aluminum salts and the like.
  • bases include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, N + (C 1-4 alkyl) 4 , and the like.
  • Representative salts include the alkali or alkaline earth salts, like lithium, sodium, potassium, calcium, and magnesium, and aluminum salts and the like of the tetrazole.
  • Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like. It should be understood that the compounds described herein also include the quaternization of any basic nitrogen- Attorney Docket No.57547-723.601 containing groups they contain. In some embodiments, water or oil-soluble or dispersible products are obtained by such quaternization. Solvates [0097] In some embodiments, the compounds described herein exist as solvates.
  • Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of the compounds described herein can be conveniently prepared or formed during the processes described herein. In addition, the compounds provided herein can exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein. Tautomers [0099] In some situations, compounds exist as tautomers.
  • the compounds described herein include all possible tautomers within the formulas described herein.
  • Tautomers are compounds that are interconvertible by migration of a hydrogen atom, accompanied by a switch of a single bond and adjacent double bond. In bonding arrangements where tautomerization is possible, a chemical equilibrium of the tautomers will exist. All tautomeric forms of the compounds disclosed herein are contemplated. The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH.
  • Preparation of the Compounds [00100] The compounds used in the reactions described herein are made according to organic synthesis techniques known to those skilled in this art, starting from commercially available chemicals and/or from compounds described in the chemical literature.
  • Suitable reference books and treatises that detail the synthesis of reactants useful in the preparation of compounds described herein, or provide references to articles that describe the preparation include for example, “Synthetic Organic Chemistry”, John Wiley & Sons, Inc., New York; S. R. Sandler et al., “Organic Functional Group Preparations,” 2nd Ed., Academic Press, New York, 1983; H. O. House, “Modern Synthetic Reactions”, 2nd Ed., W. A. Benjamin, Inc. Menlo Park, Calif.1972; T. L. Gilchrist, “Heterocyclic Chemistry”, 2nd Ed., John Wiley & Sons, New York, 1992; J.
  • the compound described herein is combined with a pharmaceutically suitable or acceptable carrier (also referred to herein as a pharmaceutically suitable (or acceptable) excipient, physiologically suitable (or acceptable) excipient, or physiologically suitable (or acceptable) carrier) selected on the basis of a chosen route of administration and standard pharmaceutical practice as described, for example, in Remington: The Science and Practice of Pharmacy (Gennaro, 21 st Ed. Mack Pub. Co., Easton, PA (2005)).
  • a pharmaceutical composition comprising a compound described herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and a pharmaceutically acceptable excipient.
  • the compound provided herein is substantially pure, in that it contains less than about 5%, or less than about 1%, or less than about 0.1% of other organic small molecules, such as unreacted intermediates or synthesis by-products that are created, for example, in one or more of the steps of a synthesis method.
  • Pharmaceutical compositions are administered in a manner appropriate to the disease to be treated (or prevented). An appropriate dose and a suitable duration and frequency of administration will be determined by such factors as the condition of the patient, the type and severity of the patient’s disease, the particular form of the active ingredient, and the method of administration.
  • an appropriate dose and treatment regimen provides the composition(s) in an amount sufficient to provide therapeutic and/or Attorney Docket No.57547-723.601 prophylactic benefit (e.g., an improved clinical outcome, such as increased overall response rate, increased duration of response, more frequent complete or partial remissions, or longer disease-free and/or overall survival, or a lessening of symptom severity.
  • prophylactic benefit e.g., an improved clinical outcome, such as increased overall response rate, increased duration of response, more frequent complete or partial remissions, or longer disease-free and/or overall survival, or a lessening of symptom severity.
  • Optimal doses are generally determined using experimental models and/or clinical trials. The optimal dose depends upon the body mass, weight, or blood volume of the patient.
  • the pharmaceutical composition is formulated for oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, intrapulmonary, intradermal, intrathecal, epidural, or intranasal administration.
  • Parenteral administration includes intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.
  • the pharmaceutical composition is formulated for intravenous injection, oral administration, inhalation, nasal administration, topical administration, or ophthalmic administration.
  • the pharmaceutical composition is formulated for oral administration.
  • the pharmaceutical composition is formulated for intravenous injection.
  • the pharmaceutical composition is formulated as a tablet, a pill, a capsule, a liquid, an inhalant, a nasal spray solution, a suppository, a gel, a colloid, a dispersion, a suspension, a solution, an emulsion, an ointment, a lotion, an eye drop, or an ear drop.
  • the pharmaceutical composition is formulated as a tablet.
  • Suitable doses and dosage regimens are determined by conventional range-finding techniques known to those of ordinary skill in the art. Generally, treatment is initiated with smaller dosages that are less than the optimum dose of the compound disclosed herein. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached.
  • Methods of Treatment include administering to the subject a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof.
  • methods for treating a Chk1-related cancer in a subject in need thereof including administering to the subject a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof.
  • the cancer includes malignant tumors whose size can be decreased, whose growth or spread can be halted, or whose symptom is in remission or alleviated and/or completely cured by deleting or suppressing and/or inhibiting functions of Chk1.
  • Malignant tumors of interest are, but not limited to, head and neck cancer, gastrointestinal cancer (esophageal cancer, gastric cancer, duodenal cancer, liver cancer, biliary tract cancer (gallbladder, bile duct cancer, etc.), pancreatic cancer, colorectal cancer (colon cancer, rectal cancer, etc.), etc.), lung cancer (non-small cell lung cancer, small cell lung cancer, squamous cell lung carcinoma, mesothelioma, etc.), breast cancer, genital cancer (ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, etc.), urinary cancer (kidney cancer, bladder cancer, prostate cancer, testicular tumor, etc.), hematopoietic tumors (leukemia, malignant lymphoma, multiple myeloma, etc.), bone Attorney Docket No.57547-723.601 and soft tissue tumors (e.g., soft tissue sarcomas and osteosarcomas), skin cancer
  • the cancer is a brain tumor (e.g., glioblastoma). In some embodiments, the cancer has metastasized in the brain.
  • the term cancer is used in accordance with its plain ordinary meaning in light of the present disclosure and refers to all types of cancer, neoplasm or malignant tumors found in mammals, including leukemias, lymphomas, melanomas, neuroendocrine tumors, carcinomas, and sarcomas.
  • Exemplary cancers that may be treated with a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, pharmaceutical compositions include acute myeloid leukemia, adrenal cortical cancer, adrenal gland cancer, bladder cancer, bone cancer, brain cancer, breast cancer (e.g., ductal carcinoma, lobular carcinoma, primary, metastatic), breast cancer, cancer of the endocrine system, cancer of the hepatic stellate cells, cancer of the pancreatic stellate cells, cervical cancer, colon cancer, colorectal cancer, ductal carcinoma, endometrial cancer, esophageal cancer, gastric cancer, genitourinary tract cancer, glioblastoma, glioma, head and neck cancer, hepatocellular carcinoma, Hodgkin’s Disease, kidney cancer, leukemia (e.g., lymphoblastic leukemia, chronic lymphocytic leukemia, hairy cell leukemia), liver cancer (e.g.,
  • the cancer is selected from bladder cancer, breast cancer, colon cancer, esophageal cancer, esophageal cancer, glioblastoma, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, salivary gland cancer, soft tissue sarcoma, squamous cell lung carcinoma, stomach cancer, and uterine cancer.
  • ecDNA mediates an important and clinically distinct mechanism of resistance to targeted therapies.
  • the one or more Chk1 inhibitor described herein may be used to treat an ecDNA+ cancer, ecDNA+ tumor or ecDNA+ tumor cells.
  • One or more Chk1 inhibitor described herein may be used to treat tumors, such as with one or more amplified oncogenes (e.g.
  • the one or more amplified oncogenes comprise non-mutant forms of the oncogene and in some cases, the amplified oncogenes comprises mutant forms of the oncogenes.
  • One or more Chk1 inhibitor described herein may be used to treat tumors for which there are no approved targeted therapies or for which highly efficacious Attorney Docket No.57547-723.601 therapies are lacking.
  • One or more Chk1 inhibitor described herein may be used to treat tumors that have developed resistance to another therapy such as a resistance to a targeted agent.
  • a tumor (or tumor cells) treated with one or more targeted agents develops resistance to a targeted agent, such as a targeted agent directed to an oncogene or a targeted agent that directly inhibits activating mutant forms of certain oncoproteins (e.g. KRAS, BRAF, EGFR) or as a consequence of focal amplification such as ecDNA- based amplification of the target gene itself, and the one or more Chk1 inhibitor described herein may be used to treat such tumors or tumor cells.
  • a targeted agent such as a targeted agent directed to an oncogene or a targeted agent that directly inhibits activating mutant forms of certain oncoproteins (e.g. KRAS, BRAF, EGFR) or as a consequence of focal amplification such as ecDNA- based amplification of the target gene itself
  • the one or more Chk1 inhibitor described herein may be used to treat such tumors or tumor cells.
  • synthetic lethality arises with one or more Chk1 inhibitors described herein in combination with a cancer targeted agent.
  • a tumor background is identified as hyper-sensitive to a Chk1 inhibitor and allows a sufficient therapeutic index to enable tolerated doses that are efficacious.
  • synthetic lethality arises with one or more Chk1 inhibitors described herein in combination with a cancer targeted agent where the tumor or tumor cells are ecDNA+.
  • Chk1 inhibition results in reduced ecDNA copy number.
  • Chk1 inhibition results in enhanced cytotoxicity in ecDNA+ cells.
  • enhanced cytotoxicity results from the combination of Chk1 inhibition and inhibition of a cancer- target, such as an oncogene.
  • a tumor or tumor cells to be treated are ecDNA+.
  • such tumor or tumor cells are determined to have an ecDNA signature.
  • a tumor or tumor cells are determined to have an ecDNA signature when the tumor or tumor cells have one or more characteristics associated with ecDNA+ tumors or tumor cells.
  • the ecDNA signature is selected from the group consisting of a gene amplification; a p53 loss of function mutation; absence of microsatellite instability (MSI-H); a low level of PD-L1 expression; a low level of tumor inflammation signature (TIS); a low level of tumor mutational burden (TMB); an increased frequency of allele substitutions, insertions, or deletions (indels); and any combination thereof.
  • Combination Therapy [00115]
  • the compound described herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof is administered in combination with a second therapeutic agent or a cancer-targeted agent.
  • the method further comprises administering a cancer-targeted therapeutic agent, directed to an activity of a protein product of a target gene.
  • the treatment with the cancer-targeted therapeutic agent and the Chk1 inhibitor disclosed herein reduces amplification or expression of the target gene in the tumor or tumor cells.
  • the cancer-targeted therapeutic agent is administered prior to the Chk1 inhibitor.
  • the cancer-targeted therapeutic agent is administered concurrently with the Chk1 inhibitor.
  • Attorney Docket No.57547-723.601 [00117]
  • the tumor or tumor cells have an ecDNA signature.
  • the tumor or tumor cells develop the ecDNA signature after administration of the cancer-targeted therapeutic agent. In some cases, the tumor or tumor cells develop the ecDNA signature prior to treatment. In some cases, the method prevents an increase of ecDNA in the tumor or tumor cells.
  • the second therapeutic agent or the cancer-targeted agent includes antimetabolites, platinum drugs, plant alkaloid drugs, and molecular targeting drugs.
  • the second therapeutic agent the cancer-targeted agent includes DNA- damaging agents.
  • the second therapeutic agent includes a radiation therapy.
  • the antimetabolites include 5-fluorouracil, 5-fluoro-2’-deoxyuridine, tegafur, tegafur-uracil, tegafur-gimeracil-oteracil, pemetrexed, trifluridine, trifluridine-tipiracil hydrochloride, fludarabine (or an active metabolite fludarabine nucleoside), cytarabine, gemcitabine, capecitabine, nelarabine, clofarabine, and DNA methylation inhibitors (decitabine, guadecitabine, azacitidine, etc.).
  • the platinum drugs include cisplatin, oxaliplatin, carboplatin, and nedaplatin.
  • the plant alkaloid drugs include microtube inhibiting drugs such as paclitaxel, docetaxel, vinblastine, vincristine, vindesine, vinorelbine, and eribulin, and topoisomerase inhibiting drugs such as irinotecan (or an active metabolite SN-38), nogitecan, and etoposide.
  • the molecular targeting drugs include ATR (ataxia telangiectasia and Rad3 related protein) inhibitors, AXL inhibitors, BRAF inhibitors, CDK4/6 inhibitors, other Chk1 (checkpoint kinase 1) inhibitors, CSF1R (colony-stimulating factor 1 receptor) inhibitors, EGFR (epidermal growth factor receptor) inhibitors, FGFR (fibroblast growth factor receptor) inhibitors, FLT3 (fms-related tyrosine kinase 3) inhibitors, HER2 inhibitors, HSP (heat shock protein) 90 inhibitors, KIT inhibitors, KRAS inhibitors, KRAS inhibitors, MDM2 (murine double minute 2) inhibitors, MDM4 (murine double minute 4) inhibitors, MET inhibitors, MYC inhibitors, PARP (poly ADP ribose polymerase) inhibitors, PDGFR (platelet-derived growth factor receptor) inhibitors, RET inhibitors, RNR
  • ATR ataxia
  • the ATR inhibitors include ART-0380, ATRN-119, ATRN-212, AZ-20, AZZ-6738, BAY-1895344, berzosertib (M-6620), BKT-300, IMP-9064, M-1774, M-4344 (VX-803), M- 6620, nLs-BG-129, NU-6027, RP-3500, SC-0245, VE-822, and VX-970.
  • the AXL inhibitors include cabozantinib and gilteritinib.
  • the BRAF inhibitors include ASN-003, AZ-304, AZ-628, DP-2874, EBI- 907, EBI-945, GDC-0879, LYN 204, NMS-P285, NMS-P730, PF-04880594, TL-241, UAI-201,and UB- 941.
  • the BRAF inhibitors include ABM-1310, agerafenib (RXDX-105), ARQ-736, BAL-3833, belvarafenib, BGB-3245, BI-882370, DAY101, lifirafenib, LUT-014, PF-07284890, PLX-8394, Attorney Docket No.57547-723.601 RX-208, VS-6766, and XL-281.
  • the BRAF inhibitors include dabrafenib, encorafenib, and vemurafenib.
  • the CDK4/6 inhibitors include AG-122275, AM-5992, AU2-94, IIIM-985, IIIM-290, GW-491619, HEC-80797, MM-D37K, MS-140, NP-102, QHRD-110, R-547, RGB-286199, RGT-419B, riviciclib, RO-0505124, THR-53, THR-79, TQB-3303, TY-302, VS2-370, XH-30002, and WXWH-0240.
  • the CDK4/6 inhibitors include auceliciclib, AT-7519, BEBT-209, BPI-1178, BPI-16350, CS-3002, fascaplysin, FCN-437, FN-1501, GLR-2007, HS-10342, lerociclib, milciclib maleate, NUV-422, ON-123300, PF-06842874, PF-06873600, PF-07220060, SHR-6390, TQB- 3616, TY-302, voruciclib, and XZP-3287.
  • the CDK4/6 inhibitors include abemaciclib, palbociclib, ribociclib, and trilaciclib.
  • the other Chk1 inhibitors include AZD-7762, BEBT-260, GDC-0575, LY- 2880070, PF-477736, prexasertib, rabusertib (LY-2603618), RG-7602, SCH-900776, SRA737, and XCCS- 605B.
  • the CSF1R inhibitors include ARRY-382, BLZ-945, and sunitinib.
  • the EGFR inhibitors include small molecule inhibitors such as APL-1898, BDTX-1535, BLU-701, BPI-361175, CH-7233163, DS-2087, E-10C, FWD-1509, IN-A008, JS-111, JS- 113, LL-191, LYN 205, neptinib, NT-004, ORIC-114, PRB-001, SIM-200, TGRX-360, WJ-13404, yinlitinib maleate, and ZSP-0391, and anti-EGFR antibodies such as 705, 707, ABX-900, CMAB-017, GB- 263, KN-023, SSGJ-612, and SHR-A1307.
  • small molecule inhibitors such as APL-1898, BDTX-1535, BLU-701, BPI-361175, CH-7233163, DS-2087, E-10C, FWD-1509, IN-A008, JS-111, JS- 113, LL-191,
  • the EGFR inhibitors include small molecule inhibitors such as abivertinib, alflutinib mesylate, agerafenib (RXDX-105), ASK-120067, BBT- 176, BDTX-189, BEBT-109, befortinib mesylate, beitatini, BPI-7711, BPI-D0316, BLU-945, CK-101, dositinib, DFP-17729, DZD-9008, epertinib, epitinib (HMPL-813), ES-072, FCN-411, FHND-9041, furmonertinib, GMA-204, Hemay-022, JRF-103, KP-673, larotinib, lazertinib, maihuatinib, marizomib, mobocertinib, naputinib tosilate, clawinib, NRC-2694
  • the EGFR inhibitors include small molecule inhibitors such as afatinib, amivantamab, aumolertinib (almonertinib), dacomitinib, erlotinib, gefitinib, icotinib, lapatinib, osimertinib, and pyrotinib, and anti-EGFR antibodies such as cetuximab, necitumumab, nimotuzumab, and panitumumab.
  • FGFR inhibitors include small molecule inhibitors such as ABSK-012, ABSK-061, AST-56100, BIO-1262, BGS-2219, EVT-601, FPI-1966, JAB-6000, KIN-3248, SAR-439115, SC-0011, and WXSH-0011, and anti- FGFR antibodies such as M-6123, OM-RCA-001.
  • FGFR inhibitors include small molecule inhibitors such as 3D-185, ABSK-011, ABSK-091, aldafermin, alofanib, AZD-4547, BFKB-8488A, BPI-17509, BPI-43487, CPL-304-110, derazantinib, E- 7090, EVER-4010001, FGF-401, fisogatinib, futibatinib, gunagratinib, H3B-6527, HH-185, HMPL-453, Attorney Docket No.57547-723.601 HS-236, ICP-105, ICP-192, infigratinib, MAX-40279, RLY-4008, rogaratinib, SAR-442501, SY-4798, TT- 00434, and zoligratinib (FF-284), and anti- FGFR antibodies such as bemarituzumab.
  • small molecule inhibitors such as 3D-185, ABSK-01
  • FGFR inhibitors include small molecule inhibitors such as erdafitinib and pemigatinib.
  • the FLT3 inhibitors include cabozantinib, gilteritinib, midostaurin, sorafenib, and sunitinib.
  • the HER2 inhibitors include small molecule inhibitors such as LL-191, NT-004, SPH-3261, and VRN-10, and anti-Her2 antibodies such as 704, 706, AbGn-110, ACE-1702, ALL- C-2137, ANT-043, AT-501, ATV:HER2, BSI-001, GB-251, Herceptarg, HK-001, IGEM-H, KL-A166, KM-254, KM-257, LIN-001, LIN-002, MI-180021, SHR-A1811, SSGJ-612, VB7-756, ZV-0201.
  • small molecule inhibitors such as LL-191, NT-004, SPH-3261, and VRN-10
  • anti-Her2 antibodies such as 704, 706, AbGn-110, ACE-1702, ALL- C-2137, ANT-043, AT-501, ATV:HER2, BSI-001, GB-251, Herceptarg, HK-001, IGEM-H, KL-
  • the HER2 inhibitors include small molecule inhibitors such as AR-788, BDTX-189, DZD- 1516, epertinib, JRF-103, larotinib, maihuatinib, mobocertinib, NRC-2694-A, pirotinib, poziotinib, tarloxotinib, TAS-0728, and ZN-A-1041, and anti-Her2 antibodies such as AC-101, ARX-788, B00-2, BAT- 1006, BAY-2701439, BCD-147, DAC-001, disitamab vedotin, DP-303c, E01001, GP-2, GQ-1001, HLX-22, KN-026, LCB-14, MB-103, MBS-301, MRG-002, MRT-201, MP-0273, PF-06804103, QL-1209, TAA-013, WLB-301, zanidata
  • the HER2 inhibitors include small molecule inhibitors such as afatinib, dacomitinib, lapatinib, neratinib, pyrotinib, and tucatinib, and anti-Her2 antibodies such as margetuximab, pertuzumab, and trastuzumab.
  • the HSP90 inhibitors include ganetespib, luminespib, and onalespib.
  • the KIT inhibitors include lenvatinib, midostaurin, pazopanib, sorafenib, and sunitinib.
  • the KRAS include small molecule inhibitors such as ABREV01, ARS- 1620, APG-1842, ATG-012, BBP-454, BEPT-607, BI-2852, BI-1823911, BPI-421286, BTX-2541, COTI- 219, IMM-1811900, JAB-21000, JAB-22000, JAB-23000, JAB-BX300, JP-002, KR-12, LYN 202, MRTX- 1133, RAS-F, RMC-6236, RMC-6291, SDGR 5, STX-301, and YL-15293, and anti-KRAS antibodies such as SBT-100, SBT-102, and SBT-300.
  • small molecule inhibitors such as ABREV01, ARS- 1620, APG-1842, ATG-012, BBP-454, BEPT-607, BI-2852, BI-1823911, BPI-421286, BTX-2541, COTI- 219, IMM-1811
  • the KRAS include small molecule inhibitors such as adagrasib, ARS-3248, D-1553, GDC-6036, JDQ-443, LY3537982, sotorasib (AMG 510), and BI 1701963.
  • MDM2 inhibitors include AD-021.32, CYC700, DS-5272, MI-1061, MI- 219, MI-43, MD-224, MK-8242, NU-8231, OM-301, PXN-527, Rigel-3, RO-2468, RO-5353, RO-5963, and SIL-43.
  • MDM2 inhibitors include ALRN-6924, APG-115, ASTX-295, ATSP-7041, BI-907828, CGM-097, idasanutlin, KRT-232 (AMG-232), MI-77301 (SAR405838, SAR299155), NVP- CGM097, RAIN-32 (milademetan), RG7112 (RO5045337), RG7388 (RG7775), serdemetan (JNJ- 26854165), siremadlin, and UBX-0101.
  • the MDM4 inhibitors include 17AAG, 489-PXN, CTX1, FL-118, Inulanolide A, K-178, and SAH-p53-8.
  • the MDM4 inhibitors include APG-115, ALRN-6924, ATSP-7041, and BI-907828.
  • the MET small molecule inhibitors such as ABP-1130, BPI-1831, BPI- 2021, BYON-3521, CG-203306, CX-1003, Debio-1144, EMD-94283, EMT-100, EMT-101, HE-003, LMV- 12, LS-177, NX-125, OMO-2, PF-4254644, PRX-MET, PTX-2173, QBH-196, RP-1400, SAB-Y14, SAR- 125844, SGX-126, SYD-3521, WXSH-0011, X-379, and XL-265, and anti-MET antibodies such as ABX- 900, GB-263, FS-101, LY-3164530, LY-3343544, PMC-002, and SAIT-301.
  • the MET small molecule inhibitors such as ABN-401, ABT-700, AMG-208, AMG-337, ARGX-111, BAY-85- 3474, BMS-817378, bozitinib, BPI-9016M, glumetinib, golvatinib tartrate, GST-HG161, HQP-8361, I-020, JNJ-38877605, kanitinib, merestinib, MK-2461, MK-8033, OMO-1, pamufetinib, S-49076, savolitinib, SPH-3348, tivantinib, SAR-125844, SCR-1515, and TPX-0022, and anti-MET antibodies such as APL- 101, CKD-702, EMB-01, EMI-137, ficlatuzumab, HLX-55, HS-10241, MCLA-129, MT-8633, NOV-1105
  • the MET small molecule inhibitors such as amivantamab, capmatinib, crizotinib, and tepotinib.
  • the PARP inhibitors include niraparib, olaparib, rucaparib, talazoparib, veliparib.
  • the PDGFR inhibitors are PDGFR ⁇ and/or PDGFR ⁇ inhibitors and include lenvatinib, midostaurin, pazopanib, sorafenib, and sunitinib.
  • the RET inhibitors include sunitinib, cabozantinib, sorafenib, lenvatinib, and vandetanib.
  • the RNR inhibitors include 5-chloro-2-(n-((1S,2R)-2-(6-fluoro-2,3- dimethylphenyl)-1-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)propyl)sulfamoyl)benzamide, cladribine, clofarabine, COH29 (N-[4-(3,4-dihydroxyphenyl)-5-phenyl-1,3-thiazol-2-yl]-3,4-dihydroxybenzamide), fluarabine, gemcitabine, hydroxyurea, motexafin gadolinium, osalmid, TAS1553, tezacitabine, and triapine.
  • the TIE2 inhibitors include cabozantinib.
  • the TRK inhibitors include cabozantinib and entrectinib.
  • the VEGFR inhibitors are inhibitors of at least one of VEGFR1, VEGFR2, and VEGFR3 and include small molecule inhibitors such as sunitinib, cabozantinib, midostaurin, sorafenib, vandetanib, pazopanib, lenvatinib, and axitinib, and anti-VEGFR antibodies such as ramucirumab.
  • Wee1 inhibitors include adavosertib, AZD1775 (MK1775), Bos-I, bosutinib, DC-859/A, Debio 0123, IMP7068, NUV-569, PD 407824, PD0166285, PD0166285, PD0407824, SC-0191, SDR-7778, SDR-7995, WEE1-IN-3, and ZN-c3.
  • the benefit experienced by a patient is increased by administering one of the compounds described herein with a second therapeutic agent (which also includes a therapeutic regimen) that also has therapeutic benefit.
  • a compound described herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof is co-administered with a second therapeutic agent, wherein the compound described herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the second therapeutic agent modulate different aspects of the disease, disorder or condition Attorney Docket No.57547-723.601 being treated, thereby providing a greater overall benefit than administration of either therapeutic agent alone.
  • the overall benefit experienced by the patient is additive of the two therapeutic agents or the patient experiences a synergistic benefit.
  • different therapeutically effective dosages of the compounds disclosed herein will be utilized in formulating a pharmaceutical composition and/or in treatment regimens when the compounds disclosed herein are administered in combination with a second therapeutic agent.
  • Therapeutically effective dosages of drugs and other agents for use in combination treatment regimens are optionally determined by means similar to those set forth hereinabove for the actives themselves.
  • the methods of prevention/treatment described herein encompasses the use of metronomic dosing, i.e., providing more frequent, lower doses in order to minimize toxic side effects.
  • a combination treatment regimen encompasses treatment regimens in which administration of a compound described herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, is initiated prior to, during, or after treatment with a second agent described herein, and continues until any time during treatment with the second agent or after termination of treatment with the second agent. It also includes treatments in which a compound described herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the second agent being used in combination are administered simultaneously or at different times and/or at decreasing or increasing intervals during the treatment period. Combination treatment further includes periodic treatments that start and stop at various times to assist with the clinical management of the patient.
  • the dosage regimen to treat, prevent, or ameliorate the condition(s) for which relief is sought is modified in accordance with a variety of factors (e.g., the disease, disorder, or condition from which the subject suffers; the age, weight, sex, diet, and medical condition of the subject).
  • the dosage regimen employed varies and, in some embodiments, deviates from the dosage regimens set forth herein.
  • dosages of the co-administered compounds vary depending on the type of co-drug employed, on the specific drug employed, on the disease or condition being treated, and so forth.
  • the compound provided herein when co-administered with a second therapeutic agent, is administered either simultaneously with the second therapeutic agent, or sequentially.
  • the multiple therapeutic agents are administered in any order or even simultaneously. If administration is simultaneous, the multiple therapeutic agents are, by way of example only, provided in a single, unified form, or in multiple forms (e.g., as a single pill or as two separate pills, as a single infusion, or as two separate infusions).
  • the compounds described herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, as well as combination therapies, are administered before, during, or after the occurrence of a disease or condition, and the timing of administering the composition containing a compound varies.
  • the compounds described herein are used as a prophylactic and are administered continuously to subjects with a propensity to develop conditions or diseases in order to prevent the occurrence of the disease or condition.
  • the compounds and compositions are administered to a subject during or as soon as possible after the onset of the symptoms.
  • a compound described herein is administered as soon as is practicable after the onset of a disease or condition is detected or suspected, and for a length of time necessary for the treatment of the disease.
  • the length required for treatment varies, and the treatment length is adjusted to suit the specific needs of each subject.
  • a compound described herein or a formulation containing the compound is administered for at least 2 weeks, about 1 month to about 5 years.
  • the compound described herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof is administered in combination with an adjuvant.
  • the therapeutic effectiveness of one of the compounds described herein is enhanced by administration of an adjuvant (i.e., by itself the adjuvant has minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced).
  • an adjuvant i.e., by itself the adjuvant has minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced.
  • EXAMPLES [00158] All final compounds were purified by either high-performance liquid chromatography (HPLC) or supercritical fluid chromatography (SFC) and were characterized by proton ( 1 H) NMR. All chemicals were purchased from commercial suppliers and used as received unless otherwise indicated. Proton nuclear magnetic resonance ( 1 H NMR) spectra were recorded on Bruker AVANCE 400 MHz spectrometers.
  • Mass spectra were obtained using LCMS on a LCMS-Agilent Attorney Docket No.57547-723.601 6125 instrument using electrospray ionization (ESI).
  • Step 2 Methyl 2-(((1R,2R)-2-aminocyclopentyl)oxy)-6-fluoro-4-(1-methylcyclopropyl)benzoate (3)
  • diethylzinc (298 mg, 2.4 mmol) in dichloromethane (20 mL) was added diiodomethane (647 mg, 2.4 mmol) dropwise.
  • diiodomethane (647 mg, 2.4 mmol) dropwise.
  • To the reaction mixture was added a solution of trifluoroacetic acid (55 ⁇ L, 0.72 mmol) in dichloromethane (3 mL) at 0 °C and the mixture was stirred for 30 min.
  • Step 3 Methyl 2-(((1R,2R)-2-((tert-butoxycarbonyl)amino)cyclopentyl)oxy)-6-fluoro-4-(1- methylcyclopropyl)benzoate (P3-1) [00164] A mixture of methyl 2-(((1R,2R)-2-aminocyclopentyl)oxy)-6-fluoro-4-(1- methylcyclopropyl)benzoate (90 mg, 0.29 mmol ), di-tert-butlydicarbonate (96 mg, 0.44 mmol ) and triethylamine (122 ⁇ L, 0.88 mmol ) in dichloromethane (5 mL) was stirred at room temperature for 2 h under nitrogen.
  • Example 1-1 5-((5-(2-(((1R,2R)-2-Aminocyclopentyl)oxy)-6-fluoro-4-methylphenyl)-1H-pyrazol-3- yl)amino)pyrazine-2-carbonitrile
  • Step 1 tert-Butyl ((1R,2R)-2-(2-(2-cyanoacetyl)-3-fluoro-5-methylphenoxy)cyclopentyl)carbamate (1)
  • methyl 2-(((1R,2R)-2-((tert-butoxycarbonyl)amino)cyclopentyl)oxy)-6-fluoro-4- methylbenzoate 470 mg, 1.28 mmol
  • acetonitrile 400 ⁇ L, 7.66 mmol
  • lithium bis(trimethylsilyl)amide 1 M in tetrahydrofuran, 3.8 mL, 3.8
  • Step 2 tert-Butyl ((1R,2R)-2-(2-(3-amino-1H-pyrazol-5-yl)-3-fluoro-5- methylphenoxy)cyclopentyl)carbamate (2) [00166] To a solution of tert-butyl ((1R,2R)-2-(2-(2-cyanoacetyl)-3-fluoro-5- methylphenoxy)cyclopentyl)carbamate (120 mg, 0.319 mmol) in ethanol (8 mL) was added hydrazine hydrate (64 ⁇ L, 1.28 mmol) and acetic acid (54 ⁇ L, 0.94 mmol).
  • Step 3 tert-Butyl ((1R,2R)-2-(2-(3-((5-cyanopyrazin-2-yl)amino)-1H-pyrazol-5-yl)-3-fluoro-5- methylphenoxy)cyclopentyl)carbamate (3) [00167] To a solution of tert-butyl ((1R,2R)-2-(2-(3-amino-1H-pyrazol-5-yl)-3-fluoro-5- methylphenoxy)cyclopentyl)carbamate (40 mg, 0.102 mmol) and 5-chloropyrazine-2-carbonitrile (17 mg, 0.123 mmol) in dimethyl sulfoxide (5 mL) was added 4-ethylmorpholine (20 ⁇ L, 0.156 mmol) and the reaction mixture was stirred at 80 °C for 8 h under nitrogen.
  • Step 4 5-((5-(2-(((1R,2R)-2-Aminocyclopentyl)oxy)-6-fluoro-4-methylphenyl)-1H-pyrazol-3- yl)amino)pyrazine-2-carbonitrile (Example 1-1) [00168] A solution of tert-butyl ((1R,2R)-2-(2-(3-((5-cyanopyrazin-2-yl)amino)-1H-pyrazol-5-yl)-3- fluoro-5-methylphenoxy)cyclopentyl)carbamate (40 mg, 0.081 mmol) in a mixture of trifluoroacetic acid and dichloromethane (5:1 v/v, 3 mL) was stirred at room temperature for 30 min.
  • the reaction mixture was evaporated and to the residue was added saturated aqueous sodium carbonate to achieve pH 8.
  • the mixture was acidifed to pH 5-6 by addition of formic acid.
  • the mixture was purified by preparative HPLC (Daisogel-C18-10-100, 30 x 250 mm, 5 um, mobile phase: ACN--H 2 O (0.1%FA), gradient: 5 ⁇ 95) to afford the title compound (18.2 mg, 56% yield).
  • LCMS Rt 1.011 min
  • ESMS m/z 394.1 [M+H] + .
  • CHK1 enzyme activity was measured using an HTRF KinEASE assay (Cisbio, catalog no. 62ST1PEC).
  • Full-length human CHK1 protein (GenBank accession number NP_001265.1) was obtained from Carna Biosciences, Inc. (Kobe, Japan, catalog no.02-117).
  • the enzyme reaction was carried out in assay buffer containing (final concentrations): CHK1 enzyme (0.012 ng/ ⁇ L), MgCl 2 (5 mM) and DTT (1 mM).
  • DMSO stock solutions were serially diluted in a 10-point concentration series in duplicate.
  • Compound solution 50 nL was added to 384-well assay plates (Greiner, catalog no.784075). To each well containing compound solution was added assay buffer solution (5 ⁇ L). Plates were centrifuged at 1000 rpm for 1 minute, then incubated at room temperature for 10 minutes. The reaction was started by addition of substrate buffer (5 ⁇ L/well) containing (final concentrations): STK substrate 1-biotin (120 nM) and ATP (1 mM). Assay plates were centrifuged at 1000 rpm for 1 minute, then incubated at room temperature for 60 minutes.
  • the reaction was stopped by addition of detection buffer (Cisbio, 10 ⁇ L) containing (final concentrations): STK antibody-cryptate (0.25 nM) and streptavidin-XL665 (7.5 nM). Plates were centrifuged at 1000 rpm for 1 minute, then incubated at 25 °C for 2 hours.
  • HTRF signal was read on an EnVision multimode plate reader (CisBio) in HTRF mode. Data were fit to dose- response curves using XLfit (IDBS, Surrey, UK) or Prism (GraphPad Software, La Jolla, CA, US) to calculate IC50 values for each compound tested.
  • Example B AlphaLisa cellular assay [00171] Compound activity in cells was measured using an AlphaLISA® SureFire® UltraTM p-CHK1 (Ser345) assay (Perkin Elmer, catalog no. ALSU-PCHK1-A10K). HT29 cells were cultured in McCoy 5A medium with 10% FBS and 1% penicillin-streptomycin and seeded to 96-well plates (Corning, catalog no. 3599). Compounds were serially diluted in DMSO over a 10-point dose range with 3-fold dilution and to each well containing cells was added compound solution. Plates were centrifuged at 1000 rpm for 30 seconds. Plates were incubated at 37 °C for 16 h.
  • a total of 3 male CD-1 mice were dosed with compound orally at a selected dose.
  • Blood, CSF, and brains were collected at a single point (2 h) after each occasion of dosing, or at multiple time points (0.5 h, 1 h, 2 h, 4 h, 8 h and 24 h) after each occasion of dosing.
  • Blood samples (approximately 0.080 mL) were collected via saphenous vein puncture and placed in K2EDTA-containing tubes. Immediately following blood collection, the samples were inverted several times and held on wet ice pending centrifugation.
  • Example D Pharmaceutical Compositions
  • Example D1 Parenteral Composition [00174] To prepare a parenteral pharmaceutical composition suitable for administration by injection, 100 mg of a water-soluble salt of a compound described herein is dissolved in DMSO and then mixed with 10 mL of 0.9% sterile saline.
  • Example D2 Oral Composition
  • 100 mg of a compound described herein is mixed with 750 mg of starch.
  • the mixture is incorporated into an oral dosage unit for, such as a hard gelatin capsule, which is suitable for oral administration.
  • Example D3 Sublingual (Hard Lozenge) Composition
  • To prepare a pharmaceutical composition for buccal delivery, such as a hard lozenge mix 100 mg of a compound described herein, with 420 mg of powdered sugar mixed, with 1.6 mL of light corn syrup, Attorney Docket No.57547-723.601 2.4 mL distilled water, and 0.42 mL mint extract.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés et des méthodes pour le traitement du cancer. Les méthodes comprennent l'administration d'une quantité thérapeutiquement efficace d'un inhibiteur de Chk1 selon l'invention à un sujet en ayant besoin.
PCT/US2023/081279 2022-11-29 2023-11-28 Inhibiteurs de checkpoint kinase 1 (chk1) et leurs utilisations Ceased WO2024118564A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263385344P 2022-11-29 2022-11-29
US63/385,344 2022-11-29

Publications (1)

Publication Number Publication Date
WO2024118564A1 true WO2024118564A1 (fr) 2024-06-06

Family

ID=91324827

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/081279 Ceased WO2024118564A1 (fr) 2022-11-29 2023-11-28 Inhibiteurs de checkpoint kinase 1 (chk1) et leurs utilisations

Country Status (2)

Country Link
TW (1) TW202440549A (fr)
WO (1) WO2024118564A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025217307A1 (fr) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Procédés de prédiction de la réponse à un inhibiteur de ras(on) et polythérapies
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
US12527790B2 (en) 2021-05-27 2026-01-20 Boundless Bio, Inc. Checkpoint kinase 1 (CHK1) inhibitors and uses thereof
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001079198A1 (fr) * 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles permettant d'inhiber des proteines kinases
WO2015120390A1 (fr) * 2014-02-10 2015-08-13 Oncothyreon Inc. Composés pharmaceutiques
WO2020043208A1 (fr) * 2018-08-31 2020-03-05 华为技术有限公司 Procédé, dispositif et système de sélection de tranche de réseau
WO2022251502A1 (fr) * 2021-05-27 2022-12-01 Boundless Bio, Inc. Inhibiteurs de la checkpoint kinase 1 (chk1) et leurs utilisations
AU2021389190A1 (en) * 2020-11-30 2023-06-29 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1h-pyrazol-3-amine derivative
WO2023226658A1 (fr) * 2022-05-25 2023-11-30 Sperogenix Therapeutics Limited Dérivés hétérocycliques à cinq chaînons contenant de l'azote en tant qu'inhibiteurs de kinase 1 de point de contrôle et leurs utilisations

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001079198A1 (fr) * 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles permettant d'inhiber des proteines kinases
WO2015120390A1 (fr) * 2014-02-10 2015-08-13 Oncothyreon Inc. Composés pharmaceutiques
WO2020043208A1 (fr) * 2018-08-31 2020-03-05 华为技术有限公司 Procédé, dispositif et système de sélection de tranche de réseau
AU2021389190A1 (en) * 2020-11-30 2023-06-29 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1h-pyrazol-3-amine derivative
WO2022251502A1 (fr) * 2021-05-27 2022-12-01 Boundless Bio, Inc. Inhibiteurs de la checkpoint kinase 1 (chk1) et leurs utilisations
WO2023226658A1 (fr) * 2022-05-25 2023-11-30 Sperogenix Therapeutics Limited Dérivés hétérocycliques à cinq chaînons contenant de l'azote en tant qu'inhibiteurs de kinase 1 de point de contrôle et leurs utilisations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DENT PAUL: "Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancer", EXPERT OPINION ON INVESTIGATIONAL DRUGS, INFORMA HEALTHCARE, UK, vol. 28, no. 12, 2 December 2019 (2019-12-02), UK , pages 1095 - 1100, XP093181167, ISSN: 1354-3784, DOI: 10.1080/13543784.2019.1694661 *
MICHAEL LAINCHBURY; IAN COLLINS: "Checkpoint kinase inhibitors: a patent review (2009 � 2010)", EXPERT OPINION ON THERAPEUTIC PATENTS, TAYLOR & FRANCIS, GB, vol. 21, no. 8, 1 August 2011 (2011-08-01), GB , pages 1191 - 1210, XP008158382, ISSN: 1354-3776, DOI: 10.1517/13543776.2011.586632 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12527790B2 (en) 2021-05-27 2026-01-20 Boundless Bio, Inc. Checkpoint kinase 1 (CHK1) inhibitors and uses thereof
WO2025217307A1 (fr) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Procédés de prédiction de la réponse à un inhibiteur de ras(on) et polythérapies
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras

Also Published As

Publication number Publication date
TW202440549A (zh) 2024-10-16

Similar Documents

Publication Publication Date Title
US11707462B2 (en) Checkpoint kinase 1 (CHK1) inhibitors and uses thereof
WO2024118564A1 (fr) Inhibiteurs de checkpoint kinase 1 (chk1) et leurs utilisations
AU2023275712A1 (en) Pyridine checkpoint kinase 1 (chk1) inhibitors and uses thereof
JP7607841B1 (ja) Ｐａｒｐ１阻害薬及びその使用
JP2024534420A (ja) 環状スルホンアミドリボヌクレオチドレダクターゼ（ｒｎｒ）阻害剤およびその使用
US20240158383A1 (en) Ribonucleotide reductase (rnr) inhibitors and uses thereof
WO2023043938A1 (fr) Inhibiteurs de ribonucléotide réductase (rnr) de sulfamide et leurs utilisations
WO2024118596A1 (fr) Combinaisons d'inhibiteurs de la checkpoint kinase 1 (chk1) et leurs utilisations
BR112024014920B1 (pt) Inibidores de parp1, composições que os compreendem, e usos dos mesmos
BR122025009667A2 (pt) Inibidores de parp1, composições que os compreendem, e usos dos mesmos
JP2025531147A (ja) 環状スルホンアミドリボヌクレオチドレダクターゼ（ｒｎｒ）阻害剤およびその使用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23898672

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23898672

Country of ref document: EP

Kind code of ref document: A1